Related Experiment Video
Updated: Jun 12, 2025
05:36
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
Published on: February 23, 2024
434
The Role of Protein Disulfide Isomerase Inhibitors in Cancer Therapy
Qiuying Nie1, Junwei Yang1, Xiedong Zhou1
1School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, 730000, China.
Chemmedchem
|September 25, 2024
Summary
Protein disulfide isomerase (PDI) is crucial for protein folding and is elevated in cancer cells. Targeting PDI offers a promising therapeutic strategy to induce cancer cell death via ER stress and the Unfolded Protein Response (UPR).
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Protein disulfide isomerase (PDI) is an endoplasmic reticulum (ER) resident enzyme vital for protein folding and disulfide bond catalysis.
- PDI's role extends to molecular chaperoning, with dysregulation linked to diverse diseases, including cancer.
- Elevated PDI levels in cancer cells support their proliferation, metastasis, and invasion, marking it as a potential cancer biomarker.
Purpose of the Study:
- To review the structure and function of PDI.
- To discuss the application of PDI inhibitors in cancer therapy.
- To identify limitations of current PDI inhibitors and propose future research directions.
Main Methods:
- Literature review of PDI structure, function, and role in disease.
- Analysis of PDI's involvement in cancer cell biology.
- Examination of existing PDI inhibitors and their therapeutic potential.
Main Results:
- PDI catalyzes critical disulfide bond formation, essential for cancer cell survival and growth.
- Targeting PDI can induce ER stress and activate the Unfolded Protein Response (UPR) pathway.
- Cancer cells exhibit higher PDI levels compared to normal cells, highlighting PDI as a therapeutic target.
Conclusions:
- PDI is a key regulator of protein homeostasis and a significant factor in cancer progression.
- Inhibiting PDI presents a viable strategy for cancer treatment by inducing apoptosis.
- Further development of novel PDI inhibitors is warranted to overcome current limitations and enhance therapeutic efficacy.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:46Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K